Abstract

A REVIEW ON TREATMENT BURDEN AND TOXICITY IN SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF BISPECIFIC ANTIBODIES IN NSCLC

Rupesh Senapati*, Mohan Kumar L., Armagan Shahid, Sneha Sarkar, Mahalakshmi A. H.

ABSTRACT

Bispecific antibodies (BsAbs) have emerged as a cornerstone of precision oncology in non-small cell lung cancer (NSCLC), offering the ability to neutralize dual signalling pathways or bridge immune cells to tumour antigens. Historically, these agents have been delivered via intravenous (IV) infusion, a method often burdened by prolonged clinical stays and high rates of systemic infusion-related reactions (IRRs). Recently, the development of subcutaneous (SC) formulations has sought to address these limitations. This review synthesizes current evidence comparing the two administration routes, focusing on pharmacological parameters, clinical safety, and patient-centric outcomes. Data indicates that SC administration provides equivalent therapeutic efficacy and pharmacokinetic non-inferiority while significantly reducing "time toxicity" and systemic adverse events. By lowering the operational and physical burden of treatment, SC formulations represent a significant step toward optimizing the delivery of bispecific therapies and improving the overall quality of care for patients with lung cancer.

Keywords: Bispecific Antibodies; NSCLC; Subcutaneous Administration; Treatment Burden.